Observational analysis shows CAR HEMATOTOX predicts superior survival in acute lymphoblastic leukemia, indicating its prognostic value post CD19 CAR-T therapy.
Key Points
HTlow patients had improved overall survival and event-free survival compared to HThigh patients, demonstrating significant prognostic implications.
Among 199 patients, delayed neutrophil recovery occurred in 26% of HTlow compared to 52% of HThigh, demonstrating a stark difference in recovery rates.
Multicenter cohort analysis validated CAR HEMATOTOX as an independent prognostic factor for treatment outcomes in acute lymphoblastic leukemia.
Results indicate that lower disease burden correlates with better outcomes, highlighting the need for early assessment efforts.